Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its ...

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition. Find out why AZN stock is a hold.

Following the label expansion, AstraZeneca's (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and older with T2D. It was previously approved for such use in adults.

AstraZeneca's diabetes drug Farxiga on Wednesday was approved by U.S. regulators for the treatment of type-2 diabetes in children 10 and older. Farxiga, which goes by generic name dapagliflozin ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s FARXIGA ® (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with ...

Farxiga, a blockbuster AstraZeneca medicine with approvals in type 2 diabetes, heart failure, and chronic kidney disease, is one of the first 10 drugs selected by CMS for negotiation.These drugs ...

Despite Jardiance's early HF edge over Farxiga, AstraZeneca’s drug has been growing nicely across its triumvirate of indications. The drug scored a hefty $4.3 billion in global sales last year, ...

London: AstraZeneca's blockbuster diabetes drug Farxiga led to significant reductions in the risk of hospitalisation and death in people with all types of heart failure, according to study data ...

LONDON - AstraZeneca's blockbuster diabetes drug Farxiga led to significant reductions in the risk of hospitalisation and death in people with all types of heart failure, according to study data ...